Federal Register Notice: FDA is making available additional draft and revised draft product-specific bioequivalence (BE) recommendations for 31 products. The recommendations provide product-specific guidance on the design of BE studies to support ANDAs. The products include recommendations for alprostadil, betamethasone dipropionate, ciclesonide, and elvitegravir. To view this notice, click here.
